Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, discusses the side effects induced by treatment with betibeglogene autotemcel (beti-cel) in patients with transfusion-dependent β-thalassemia. Data has shown that beti-cel may impact fertility, and it is therefore important to conduct fertility management prior to treatment. A further follow-up is required to evaluate the potential of insertional mutagenesis and induction of leukemia. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.